143 related articles for article (PubMed ID: 23867014)
1. Assessment of viral replication in eggs and HA protein yield of pre-pandemic H5N1 candidate vaccine viruses.
Jing X; Soto J; Gao Y; Phy K; Ye Z
Vaccine; 2013 Aug; 31(38):4091-7. PubMed ID: 23867014
[TBL] [Abstract][Full Text] [Related]
2. Improvement of H5N1 influenza vaccine viruses: influence of internal gene segments of avian and human origin on production and hemagglutinin content.
Abt M; de Jonge J; Laue M; Wolff T
Vaccine; 2011 Jul; 29(32):5153-62. PubMed ID: 21624413
[TBL] [Abstract][Full Text] [Related]
3. Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1).
Harvey R; Wheeler JX; Wallis CL; Robertson JS; Engelhardt OG
Vaccine; 2008 Dec; 26(51):6550-4. PubMed ID: 18840494
[TBL] [Abstract][Full Text] [Related]
4. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
[TBL] [Abstract][Full Text] [Related]
5. Development of influenza A(H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs.
Ridenour C; Johnson A; Winne E; Hossain J; Mateu-Petit G; Balish A; Santana W; Kim T; Davis C; Cox NJ; Barr JR; Donis RO; Villanueva J; Williams TL; Chen LM
Influenza Other Respir Viruses; 2015 Sep; 9(5):263-70. PubMed ID: 25962412
[TBL] [Abstract][Full Text] [Related]
6. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination.
Schmeisser F; Vodeiko GM; Lugovtsev VY; Stout RR; Weir JP
Vaccine; 2010 Mar; 28(12):2442-9. PubMed ID: 20074687
[TBL] [Abstract][Full Text] [Related]
7. Increase in viral yield in eggs and MDCK cells of reassortant H5N1 vaccine candidate viruses caused by insertion of 38 amino acids into the NA stalk.
Zhang W; Xue T; Wu X; Zhang P; Zhao G; Peng D; Hu S; Wang X; Liu X; Liu W; Liu X
Vaccine; 2011 Oct; 29(45):8032-41. PubMed ID: 21864614
[TBL] [Abstract][Full Text] [Related]
8. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
[TBL] [Abstract][Full Text] [Related]
9. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines.
Kapteyn JC; Porre AM; de Rond EJ; Hessels WB; Tijms MA; Kessen H; Slotboom AM; Oerlemans MA; Smit D; van der Linden J; Schoen P; Thus JL
Vaccine; 2009 Feb; 27(9):1468-77. PubMed ID: 19110022
[TBL] [Abstract][Full Text] [Related]
10. Generation of recombinant pandemic H1N1 influenza virus with the HA cleavable by bromelain and identification of the residues influencing HA bromelain cleavage.
Wang W; Suguitan AL; Zengel J; Chen Z; Jin H
Vaccine; 2012 Jan; 30(5):872-8. PubMed ID: 22172510
[TBL] [Abstract][Full Text] [Related]
11. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
[TBL] [Abstract][Full Text] [Related]
12. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate.
Horimoto T; Takada A; Fujii K; Goto H; Hatta M; Watanabe S; Iwatsuki-Horimoto K; Ito M; Tagawa-Sakai Y; Yamada S; Ito H; Ito T; Imai M; Itamura S; Odagiri T; Tashiro M; Lim W; Guan Y; Peiris M; Kawaoka Y
Vaccine; 2006 Apr; 24(17):3669-76. PubMed ID: 16378663
[TBL] [Abstract][Full Text] [Related]
13. Suboptimal protection against H5N1 highly pathogenic avian influenza viruses from Vietnam in ducks vaccinated with commercial poultry vaccines.
Cha RM; Smith D; Shepherd E; Davis CT; Donis R; Nguyen T; Nguyen HD; Do HT; Inui K; Suarez DL; Swayne DE; Pantin-Jackwood M
Vaccine; 2013 Oct; 31(43):4953-60. PubMed ID: 23994373
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
Vaccine; 2009 Oct; 27(45):6296-9. PubMed ID: 19840663
[TBL] [Abstract][Full Text] [Related]
15. Single dose of oil-adjuvanted inactivated vaccine protects chickens from lethal infections of highly pathogenic H5N1 influenza virus.
Hwang SD; Kim HS; Cho SW; Seo SH
Vaccine; 2011 Mar; 29(11):2178-86. PubMed ID: 21172378
[TBL] [Abstract][Full Text] [Related]
16. Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays.
Lorbetskie B; Wang J; Gravel C; Allen C; Walsh M; Rinfret A; Li X; Girard M
Vaccine; 2011 Apr; 29(18):3377-89. PubMed ID: 21397719
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of hemagglutinin from A/Bar-headed Goose/Qinghai/1A/05 and A/Anhui/1/05 strains of H5N1 influenza viruses produced in Nicotiana benthamiana plants.
Shoji Y; Farrance CE; Bi H; Shamloul M; Green B; Manceva S; Rhee A; Ugulava N; Roy G; Musiychuk K; Chichester JA; Mett V; Yusibov V
Vaccine; 2009 May; 27(25-26):3467-70. PubMed ID: 19200814
[TBL] [Abstract][Full Text] [Related]
18. The antigenic architecture of the hemagglutinin of influenza H5N1 viruses.
Velkov T; Ong C; Baker MA; Kim H; Li J; Nation RL; Huang JX; Cooper MA; Rockman S
Mol Immunol; 2013 Dec; 56(4):705-19. PubMed ID: 23933511
[TBL] [Abstract][Full Text] [Related]
19. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
[TBL] [Abstract][Full Text] [Related]
20. A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines.
Schmeisser F; Jing X; Joshi M; Vasudevan A; Soto J; Li X; Choudhary A; Baichoo N; Resnick J; Ye Z; McCormick W; Weir JP
Influenza Other Respir Viruses; 2016 Mar; 10(2):134-40. PubMed ID: 26616263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
